Surgery Websites
Transplantation Research Lab »  People »  Principal Investigators »  Flavio Vincenti, M.D.
Flavio Vincenti, M.D.

Flavio Vincenti, M.D.

Clinical Professor of Medicine and Surgery
Departments of Medicine and Surgery
Endowed Chair in Kidney Transplantation

Contact Information

Academic Office
(415) 353-8390
Fax: 415.353.8974
flavio.Vincenti@ucsfmedctr.org

Appointments
(415) 353-1888 Liver
(415) 353-1551 Kidney and Pancreas
Open Popup
  • American University Medical Center of Beirut, BS  - 1971
  • Universite Saint-Joseph Faculty of Medicine, MD - 1975
  • Internal Medicine Residency: American University of Beirut Medical Center
  • Fellow in Nephrology, Emory University School of Medicine, Atlanta, Georgia, July 1, 1973 - June 30, 1975
  • Research Fellow, National Kidney Foundation, July 1, 1974 - June 30, 1975
  • Fellow in Cardiovascular Research Institute (Nephrology) University of California, San Francisco, July 1, 1975 - June 30, 1976
  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Nephrology - Subspecialty
  • Chronic Kidney Disease
  • End Stage Renal Disease (Kidney Failure)
  • Internal Medicine
  • Kidney Transplantation
  • Living Kidney Donor Transplantation
  • Pancreas Transplantation
  • Transplant Nephrology
  • Transplant Nephrology

Dr. Flavio Vincenti, a kidney and pancreas transplant specialist, is board certified in internal medicine and nephrology. He came to UCSF Medical Center in 1975 for a transplant nephrology fellowship and was appointed a member of the kidney transplant team.

His memberships in professional organizations include the American Society of Nephrology, American Society of Transplantation, International Society of Nephrology and Transplantation Society. He is a co-leader of the kidney section of the Immune Tolerance Network for kidney transplantation. In addition, he is on the editorial board of the American Journal of Kidney Diseases and Graft.

In 1978, Vincenti was one of the authors of an article in the New England Journal of Medicine about the role of blood transfusions in improving kidney transplants. He also wrote a series of articles on the complications of transplants and has been a leading investigator and author on the use of anti interleukin 2 receptor monoclonal antibodies. In addition, he is a proponent of minimizing immunosuppressive drugs after transplants.

 
  1. Hirose R, Vincenti F. Review of transplantation--1999. Clin Transpl. 1999;:295-315. Review.
  2. Norman DJ, Vincenti F, de Mattos AM, Barry JM, Levitt DJ, Wedel NI, Maia M, Light SE. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation. 2000 Dec 27;70(12):1707-12.
  3. Korsun A, Vincenti F, Ruck D, Whitelaw N, Ladoulis C, Whitelaw G. The role of daclizumab in balancing resources for inpatient and outpatient transplant services. Prog Transplant. 2000 Mar;10(1):21-4. Review.
  4. Ekberg H, Backman L, Tufveson G, Tyden G, Nashan B, Vincenti F. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis. Transpl Int. 2000;13(2):151-9.
  5. Pirsch J, Bekersky I, Vincenti F, Boswell G, Woodle ES, Alak A, Kruelle M, Fass N, Facklam D, Mekki Q. Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability. J Clin Pharmacol. 2000 May;40(5):527-32.
  6. Chang GJ, Mahanty HD, Vincenti F, Freise CE, Roberts JP, Ascher NL, Stock PG, Hirose R. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin Transplant. 2000 Dec;14(6):550-4.
  7. Vincenti F. Interleukin-2 receptor monoclonal antibodies in renal transplantation: current use and emerging regimens. Transplant Proc. 2001 Nov-Dec;33(7-8):3169-71. No abstract available.
  8. Bumgardner GL, Hardie I, Johnson RW, Lin A, Nashan B, Pescovitz MD, Ramos E, Vincenti F; Phase III Daclizumab Study Group. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation. 2001 Sep 15;72(5):839-45.
  9. Bumgardner GL, Ramos E, Lin A, Vincenti F; Daclizumab Triple Therapy and Double Therapy Groups. Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function. Transplantation. 2001 Aug 27;72(4):642-7.
  10. Vincenti F. Is complete avoidance of calcineurin inhibitors or steroids now possible? Importance of patient selection and choice of regimen. Transplant Proc. 2001 Jun;33(4 Suppl):11S-18S. No abstract available.
  11. Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J, Johnson R, Kuypers D, Stuart F, Khanna A, Navarro M, Nashan B. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation. 2001 May 15;71(9):1282-7.
  12. Vincenti F. Tacrolimus (FK 506) in kidney transplantation: five-year survival results of the U.S. multicenter, randomized, comparative trial. Transplant Proc. 2001 Feb-Mar;33(1-2):1019-20. No abstract available.
  13. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Neylan J, Roza A, Somberg K. Rapid steroid withdrawal versus standard steroid therapy in patients treated with basiliximab, cyclosporine, and mycophenolate mofetil for the prevention of acute rejection in renal transplantation. Transplant Proc. 2001 Feb-Mar;33(1-2):1011-2. No abstract available.
  14. Vincenti F. The role of newer monoclonal antibodies in renal transplantation. Transplant Proc. 2001 Feb-Mar;33(1-2):1000-1. Review. No abstract available.
  15. Vincenti F. What's in the pipeline? New immunosuppressive drugs in transplantation. Am J Transplant. 2002 Nov;2(10):898-903. Review.
  16. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002 Mar 15;73(5):775-82. Erratum in: Transplantation 2002 Apr 27;73(8):1370.
  17. Parasrampuria DA, Lantz MV, Birnbaum JL, Vincenti FG, Benet LZ. Effect of calcineurin inhibitor therapy on P-gp expression and function in lymphocytes of renal transplant patients: a preliminary evaluation. J Clin Pharmacol. 2002 Mar;42(3):304-11.
  18. Posselt AM, Vincenti F, Bedolli M, Lantz M, Roberts JP, Hirose R. CD69 expression on peripheral CD8 T cells correlates with acute rejection in renal transplant recipients. Transplantation. 2003 Jul 15;76(1):190-5.
  19. Vincenti F. Immunosuppression minimization: current and future trends in transplant immunosuppression. J Am Soc Nephrol. 2003 Jul;14(7):1940-8. Review. No abstract available.
  20. Vanrenterghem Y, Ponticelli C, Morales JM, Abramowicz D, Baboolal K, Eklund B, Kliem V, Legendre C, Morais Sarmento AL, Vincenti F. Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant. 2003 Jul;3(7):835-45.
  21. Vincenti F. New monoclonal antibodies in renal transplantation. Minerva Urol Nefrol. 2003 Mar;55(1):57-66. Review.
  22. Vincenti F, Stock P. De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco. Transplant Proc. 2003 May;35(3 Suppl):183S-186S.
  23. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant. 2003 Mar;3(3):306-11.
  24. Vincenti F, Pace D, Birnbaum J, Lantz M. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transplant. 2003 Jan;3(1):50-2.
  25. Pescovitz MD, Bumgardner G, Gaston RS, Kirkman RL, Light S, Patel IH, Nieforth K, Vincenti F. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. Clin Transplant. 2003 Dec;17(6):511-7.
  26. Ramos E, Vincenti F, Lu WX, Shapiro R, Trofe J, Stratta RJ, Jonsson J, Randhawa PS, Drachenberg CB, Papadimitriou JC, Weir MR, Wali RK. Retransplantation in patients with graft loss caused by polyoma virus nephropathy. Transplantation. 2004 Jan 15;77(1):131-3.
  27. Armuzzi A, De Pascalis B, Lupascu A, Fedeli P, Leo D, Mentella MC, Vincenti F, Melina D, Gasbarrini G, Pola P, Gasbarrini A. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci. 2004 Sep-Oct;8(5):231-3.
  28. Lipshutz GS, Flechner SM, Govani MV, Vincenti F. BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen. Am J Transplant. 2004 Dec;4(12):2132-4.
    Vincenti F. Interleukin-2 receptor antagonists and aggressive steroid minimization strategies for kidney transplant patients. Transpl Int. 2004 Sep;17(8):395-401. Epub 2004 Sep 8. Review.
  29. Vincenti F. A decade of progress in kidney transplantation. Transplantation. 2004 May 15;77(9 Suppl):S52-61. Review.
  30. Vincenti F, Brennan TV, Fuller TF, Feng S. Optimizing the use of cyclosporine (Neoral) for recipients of living donor kidneys. Transplant Proc. 2004 Mar;36(2 Suppl):50S-53S. No abstract available.
  31. Ghiggeri GM, Carraro M, Vincenti F. Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins: theory and therapy. Nephrol Dial Transplant. 2004 May;19(5):1036-40. Epub 2004 Mar 5. Review. No abstract available.
  32. Vincenti F, Ghiggeri GM. Recurrent focal glomerulosclerosis. Am J Transplant. 2005 Oct;5(10):2595.
  33. Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B; Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005 Aug 25;353(8):770-81.
  34. Lauritano EC, Gabrielli M, Lupascu A, Santoliquido A, Nucera G, Scarpellini E, Vincenti F, Cammarota G, Flore R, Pola P, Gasbarrini G, Gasbarrini A. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005 Jul 1;22(1):31-5.
  35. Vincenti F. A drug of the past, a lesson for the future. Pediatr Transplant. 2005 Jun;9(3):267-8. No abstract available.
  36. Vincenti F, Ghiggeri GM. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant. 2005 Jun;5(6):1179-85. Review.
  37. Wilkinson A, Davidson J, Dotta F, Home PD, Keown P, Kiberd B, Jardine A, Levitt N, Marchetti P, Markell M, Naicker S, O'Connell P, Schnitzler M, Standl E, Torregosa JV, Uchida K, Valantine H, Villamil F, Vincenti F, Wissing M. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant. 2005 Jun;19(3):291-8. Review.
  38. Vincenti F, Tuncer M, Castagneto M, Klinger M, Friman S, Scheuermann EH, Wiecek A, Russ GR, Martinek A, Nonnast-Daniel B; DIRECT Study Group. Prospective, multicenter, randomized trial to compare incidence of new-onset diabetes mellitus and glucose metabolism in patients receiving cyclosporine microemulsion versus tacrolimus after de novo kidney transplantation. Transplant Proc. 2005 Mar;37(2):1001-4.
  39. Vincenti F, Rostaing L; DIRECT (Diabetes Incidence after REnal Transplantation: Neoral C2 monitoring versus Tacrolimus) investigators. Rationale and design of the DIRECT study: a comparative assessment of the hyperglycemic effects of tacrolimus and cyclosporine following renal transplantation. Contemp Clin Trials. 2005 Feb;26(1):17-24. Epub 2005 Jan 27.
  40. Peddi VR, Jensik S, Pescovitz M, Pirsch J, Adler SH, Thistlethwaite JR, Vincenti F, Cohen DJ. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant. 2005 Feb;19(1):130-6.
  41. Woodle ES, Vincenti F, Lorber MI, Gritsch HA, Hricik D, Washburn K, Matas AJ, Gallichio M, Neylan J. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. Am J Transplant. 2005 Jan;5(1):157-66.
  42. Vincenti F. Chronic induction. What's new in the pipeline. Contrib Nephrol. 2005;146:22-9. Review.

Site Directory
    X